Michael Almstetter und Ceo - Info zur Person

(1 - 21 von 21

)

Origenis GmbH Announces Global License and Collaboration ...

“We are excited to apply our technology platform as well as our interdisciplinary approach and chemical expertise to a novel class of compounds supporting Expansion in their efforts to develop medicines for RNA-mediated diseases,” Michael Almstetter, CEO of Origenis.

BIO CEO & Investor Conference | Biotechnolo Qwoted

app.qwoted.com

Mr. Michael Almstetter Ceo, Origenis Gmbh. Mr. Albert Gianchetti President and Ceo, Xylocor The…utics, Inc. Dr. Christopher J. Burns › event-bio...

News on kinase inhibitors - bionity.comwww.bionity.com › news › topic

www.bionity.com

Michael Almstetter, CEO and ... more. Watchlist. OCTIMET secures over EUR 11 million to develop its highly selective MET kinase inhibitors. 19-Jan

Luc Des…s's email & phone - Neuron23 - Datanyze

Luc's Workplace · Luc's CEO is Michael Almstetter · Luc is located in United States · Luc has been Vice President, Translational Research & Discovery in Neuron › people

Biographie von Michael Almstetter - The Official Board

www.theofficialboard.de

Michael Almstetter ist derzeit Director bei Neuron23. Bei Neuron23 hat Michael Almstetter 11 Kollegen einschließlich Mario Saltarelli (CEO), Beth Seidenberg ...

Team | Origenis | Planegg

www.origenis.de

Our Team of inventors and founders and managers, CEO chemist, CSO biochemist, COO biologist, Michael Almstetter, Dr. Michael Thormann, Dr. Andreas Treml

Origenis GmbH gibt die Erweiterung einer weltweiten Lizenz

www.presseportal.de

— Michael Almstetter, CEO, Dr. Peter Seufer-Wasserthal, CBO, Tel: +49 (0) , Tel: +49 (0) , ... › ...

Twitter-Nachrichten: Uživatel Big4Bio:Boston na Twitteru: „From @LaVoieGroup: Q&A ...

@big4bioBOS. From. @LaVoieGroup. : Q&A with Michael Almstetter, CEO, Origenis http://bit.ly/2lfe3Cg. Obrázek. 9:00 odp. · ·Hootsuite. › status

About the 17th Annual Biotech in Europe Forum

www.sachsforum.com

... Michael Stein, Executive Chairman of the Board, Valo The…utics Ltd. Michael Almstetter, CEO, Origenis GmbH; Michael Bauer, CEO, Cellestia Biotech AG ... › ...

Origenis GmbH Announces Research Collaboration with U.S. ...uk.finance.yahoo.com › news › origenis-gmbh-a...

uk.finance.yahoo.com

Contact. Michael Almstetter, CEO Tel: +49 (0) · Reblog · Share · Tweet · Share.

Agenda

www.neurotechpartneringeurope.com

Xavier Paoli, Chief Commercial Officer; VP R&D Operations, Pharnext. Selective Kinase Inhibition in the Brain. Michael Almstetter, CEO, Origenis GmbH.

Origenis Appoints Thomas Loeser as Chief Financial Yahoo Finance

finance.yahoo.com

Origenis' CEO Michael Almstetter commented: “We are delighted to expand our executive management team with Thomas. With his proven ...

Agenda Archive

www.neurotechpartnering.com

Michael Almstetter, CEO, Origenis. Nader Yaghoubi, President and CEO, PathMaker Neurosystems Inc. Jim DeMesa, CEO, Emerald Health …s.

Origenis GmbH Announces Global License and Collaboration ...

finance.yahoo.com

... of compounds supporting Expansion in their efforts to develop medicines for RNA-mediated diseases,” Michael Almstetter, CEO of Origenis.

biotechnologie.de

“Wir freuen uns darauf unsere Technologie Plattform, unseren interdisziplinären Ansatz und die chemische Expertise auf eine neue Klasse von Targets und Verbindungen anzuwenden und damit Expansion bei ihrer Entwicklung neuer Me…amente für RNA-vermittelte Krankheiten zu unterstützen,” erklärt Michael Almstetter, CEO von Origenis.

Barbara Beck
Ryan Crotin
Robert Eckl

Bruno Reichart
Stefan Heck
Joachim Vogt

Personen
Vorname "Michael" (149265)
Name "Almstetter" (7)

sortiert nach Relevanz / Datum

Erweiterte Suche

Person-Suchen: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Michael Almstetter und Ceo Person-Info

Origenis GmbH Announces Global License and Collaboration ...

BIO CEO & Investor Conference | Biotechnolo Qwoted

News on kinase inhibitors - bionity.comwww.bionity.com › news › topic

Luc Des…s's email & phone - Neuron23 - Datanyze

Biographie von Michael Almstetter - The Official Board

Team | Origenis | Planegg

Origenis GmbH gibt die Erweiterung einer weltweiten Lizenz

Twitter-Nachrichten: Uživatel Big4Bio:Boston na Twitteru: „From @LaVoieGroup: Q&A ...

About the 17th Annual Biotech in Europe Forum

Origenis GmbH Announces Research Collaboration with U.S. ...uk.finance.yahoo.com › news › origenis-gmbh-a...

Agenda

Origenis Appoints Thomas Loeser as Chief Financial Yahoo Finance

Agenda Archive

Origenis GmbH Announces Global License and Collaboration ...

biotechnologie.de

LifeScience Update - Veranstaltungsempfehlung Biotech-Press Lounge

Origenis GmbH Announces Global pre-IPO PHARMA

Origenis Appoints Thomas Loeser as Chief Financial Officer

Origenis GmbH Announces Global License Biotech Finances

Origenis founds biotech company Neuron23

Origenis gründet zusammen mit Starinvestor Kleiner Perkins ...

Alle Infos zum Namen "Michael Almstetter"